Peijia Medical Limited (9996.HK)
- Previous Close
5.750 - Open
5.750 - Bid 5.760 x --
- Ask 5.800 x --
- Day's Range
5.680 - 5.860 - 52 Week Range
2.160 - 6.050 - Volume
660,000 - Avg. Volume
1,873,921 - Market Cap (intraday)
3.858B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
-- - EPS (TTM)
-0.370 - Earnings Date Mar 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.64
Peijia Medical Limited, together with its subsidiaries, engages in the research, development, manufacturing, and sales of transcatheter valve therapeutic and neurointerventional procedural medical devices in the People's Republic of China. It operates through Transcatheter Valve Therapeutic Business, Neurointerventional Business, and Future Technology Business segments. The company products include transcatheter aortic valve replacement (TAVR) systems, crosslinked dry-tissue and polymeric tri leaflet TAVR systems, transcatheter aortic valve systems, transseptal mitral valve replacement systems, transfemoral balloon catheter, introducer sheath, pre-shaped guidewire, detachable coils, balloon guide catheter, aspiration catheter, stent retriever, delivery balloon dilatation catheter, balloon dilatation catheter, microcatheter, micro guidewire, micro guidewire, guide catheter, distal access guide catheter, intermediate catheter, and power supply. In addition, it engages in the trading and holding business. Peijia Medical Limited was incorporated in 2012 and is headquartered in Suzhou, the People's Republic of China.
www.peijiamedical.comRecent News: 9996.HK
View MorePerformance Overview: 9996.HK
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9996.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9996.HK
View MoreValuation Measures
Market Cap
3.82B
Enterprise Value
3.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.77
Price/Book (mrq)
1.74
Enterprise Value/Revenue
4.99
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-36.81%
Return on Assets (ttm)
-5.36%
Return on Equity (ttm)
-10.58%
Revenue (ttm)
615.48M
Net Income Avi to Common (ttm)
-226.58M
Diluted EPS (ttm)
-0.370
Balance Sheet and Cash Flow
Total Cash (mrq)
712.52M
Total Debt/Equity (mrq)
12.39%
Levered Free Cash Flow (ttm)
-125.29M